POSACONAZOL ACCORD 300mg perfusive solution concentrate medication leaflet

J02AC04 posaconazole • Antiinfectives for systemic use | Antimycotics for systemic use | Triazole derivatives


Posaconazolum is an antifungal medication used for the prevention and treatment of severe fungal infections, such as invasive aspergillosis or oropharyngeal candidiasis.
It belongs to the triazole class and works by inhibiting the synthesis of ergosterol, an essential component of the fungal cell membrane, leading to fungal destruction.

Posaconazolum is particularly indicated for immunocompromised patients, such as those who have undergone organ transplants or are undergoing chemotherapy.
The medication is available as an oral suspension, tablets, or injectable solution, with the dosage adjusted based on the severity of the infection and the patient's condition.

Common side effects include nausea, diarrhea, headaches, and elevated liver enzyme levels.
In rare cases, more serious adverse effects may occur, such as hepatotoxicity or severe allergic reactions.

It is important for patients to strictly follow their doctor's recommendations and undergo regular liver function tests during treatment.
Posaconazolum may interact with other medications, so patients should inform their doctor about all treatments they are taking.

General data about POSACONAZOL ACCORD 300mg

Substance: posaconazole

Date of last drug list: 01-08-2024

Commercial code: W70390002

Concentration: 300mg

Pharmaceutical form: perfusive solution concentrate

Packing volume: 20 ml

Product type: generic

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: PHARMADOX HEALTHCARE LTD. - MALTA

Holder: ACCORD HEALTHCARE POLSKA SP. Z O.O. - POLONIA

Number: 15208/2023/01

Shelf life: 2 years

Concentrations available for posaconazole

100mg, 300mg, 40mg/ml

Other substances similar to posaconazole